source
- New evidence links AAV gene therapies to tumor risk, raising safety concernsRecent cases reported this year provide strong evidence that adeno-associated viruses (AAVs), the vectors used to deliver therapeutic genes, can trigger tumor formation. The findings settle a two‑d…
- Amgen's Repatha shows reduced heart attack risk while Satellos alters Duchenne trial endpointSatellos Bioscience announced a change to the primary endpoint of its ongoing Duchenne muscular dystrophy trial of the investigational small‑molecule forazapadin, shifting focus to a measure of mus…